Nephros (NEPH) Cash & Equivalents (2010 - 2026)

Nephros has reported Cash & Equivalents for 17 years, with the latest figure at $4.7 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 7.43% year-over-year to $4.7 million in Q2 2026; TTM through Jun 2026 was $4.7 million, a 7.43% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, up 43.62% from the prior year.
• Cash & Equivalents was $4.7 million for Q2 2026 at Nephros, up from $4.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $5.4 million in Q1 2022, with the low at $2.5 million in Q3 2024.
• Average Cash & Equivalents over 5 years is $4.2 million, with a median of $4.1 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents tumbled 49.52% in 2022, then jumped 110.46% in 2025.
• Over 5 years, Cash & Equivalents stood at $3.6 million in 2022, then advanced by 18.52% to $4.3 million in 2023, then declined by 12.7% to $3.8 million in 2024, then jumped by 43.62% to $5.4 million in 2025, then decreased by 13.02% to $4.7 million in 2026.
• The last three Cash & Equivalents figures came in at $4.7 million (Q2 2026), $4.0 million (Q1 2026), and $5.4 million (Q4 2025), per Business Quant data.